Merck has opened the application period for its 6th round of its Accelerator program for both Germany and international startups.
Set to close November 13, 2017 for the spring 2018 intake, the Accelerator program looking for startups in life science, performance materials, and healthcare categories as well as bio-interfaces and sensors, precision farming, 3D printing, future organic chemistry solutions, microbiome research and smart site management.
Located directly at the heart of Merck’s headquarters, the new Merck Innovation Center includes a co-creation room, library and a maker space.
According to Michael Gamber, Head of the Innovation Center: “Situating even more experts and startups at the same site allows us to focus more on effective support and collaboration. By adding additional search fields, we are taking into account the rise of trends from 3D printing to bio-interfaces and sensors. We are looking forward to the variety of topics presented by the incoming twelve teams to identify future options for Merck.”
The application window is now open until November 13. In spring 2018, the selected teams will move into the Merck Innovation Center in Darmstadt, Germany in order to develop their projects over the course of three months.
The Merck Accelerator program in Darmstadt supports early-stage companies that are focused on the fields of healthcare, life science, performance materials, and additional search fields, such as bio-interfaces and sensors, enablers of precision farming, 3D pill printing, future organic chemistry, microbiome research, and smart site management. The program focuses primarily on digital business models.
Selected companies will receive office space at the Merck Innovation Center in Darmstadt, as well as mentoring and in-depth coaching from a network comprising over 50,000 experts from 66 countries. Additionally, they will receive financial support of up to € 50,000.
Oculyze, Living Brain, Labfolder, and MedicSen are current participants of the program. In Nairobi, the Coolfinity, SophieBot and Wellthy Therapeutics teams are further developing their innovations.
